Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction

Purpose of Review The goal of this review is to highlight work identifying mechanisms driving hypercholesterolemia-mediated endothelial dysfunction. We specifically focus on cholesterol-protein interactions and address specific questions related to the impact of hypercholesterolemia on cellular cholesterol and vascular endothelial function. We describe key approaches used to determine the effects of cholesterol-protein interactions in mediating endothelial dysfunction under dyslipidemic conditions. Recent Findings The benefits of removing the cholesterol surplus on endothelial function in models of hypercholesterolemia is clear. However, specific mechanisms driving cholesterol-induced endothelial dysfunction need to be determined. In this review, we detail the latest findings describing cholesterol-mediated endothelial dysfunction, highlighting our studies indicating that cholesterol suppresses endothelial Kir2.1 channels as a major underlying mechanism. Summary The findings detailed in this review support the targeting of cholesterol-induced suppression of proteins in restoring endothelial function in dyslipidemic conditions. The identification of similar mechanisms regarding other cholesterol-endothelial protein interactions is warranted.


Introduction
Plasma hypercholesterolemia, elevated levels of low-density lipoproteins (LDL), is one of the major predictors and risk factors for the development of atherosclerosis. The mechanisms responsible for the atherogenic effects of LDL are primarily attributed to the penetration and retention of LDL particles in the extracellular sub-endothelium space, where they undergo pro-inflammatory modifications by aggregation and oxidation and induce recruitment of monocytes that differentiate into macrophages to become cholesterol-laden foam cells [1,2]. Accumulation of cholesterol can be in the form of cholesterol esters that can be stored intracellularly or non-esterified (free) cholesterol, an essential and major lipid component of the plasma membrane in all mammalian cells, where it exerts numerous effects on the function of membrane proteins both directly and indirectly [3][4][5]. Earlier studies found a strong correlation between free cholesterol content of the lesions and lesion necrosis due to cholesterol toxicity leading to macrophage death [6,7]. The toxicity of cholesterol was attributed to a change in the biophysical properties of the ER membranes and ER stress [8] and cholesterol-induced interaction with membrane receptors [9].
A key early stage of atherosclerosis development, however, is impairment of the endothelium, the inner lining of the blood vessels. In this review, we focus on the accumulating evidence that hypercholesterolemia-induced increase in the membrane cholesterol content of endothelial cells plays a major role in endothelial dysfunction via direct cholesterolprotein interactions.

Impact of Plasma Hypercholesterolemia on Endothelial Free Cholesterol
The first key question is what is the impact of plasma hypercholesterolemia on cellular and membrane cholesterol content of endothelial cells? In general, membrane cholesterol of mammalian cells is maintained within a relatively narrow range of a physiological set point regulated by sterol sensing feedback mechanisms [10][11][12]. Numerous studies also showed, however, that cholesterol content of cellular membranes in cultured cells, including endothelial cells, can be increased ~ twofold by the exposure to a cyclic oligosaccharide methyl-β-cyclodextrin (MβCD) saturated with free cholesterol [13]. Surprisingly, while endothelial dysfunction is well recognized to be a key early step in hypercholesterolemia-induced vascular dysfunction and initiation of atherosclerosis, only few studies assessed the level of free cholesterol in endothelial cells under hypercholesterolemic conditions. First, our studies showed that plasma hypercholesterolemia in vivo [14] and exposure to high levels of LDL in vitro [15, 16••] both result in significant elevation of free cholesterol in endothelial cells. Specifically, using a porcine model of diet-induced hypercholesterolemia, we showed that aortic endothelial cells freshly isolated from hypercholesterolemic pigs contained a twofold higher free cholesterol level, as compared to cells isolated from aortas of pigs that were maintained on regular low-cholesterol diet (~ 20 μg cholesterol/mg protein vs. ~ 40 μg cholesterol/mg protein) [14]. A similar elevation of free cholesterol was observed when human aortic endothelial cells were exposed to VLDL or to acLDL but not to oxLDL, the latter having no effect on endothelial cellular cholesterol [14]. In this early study, we focused on the modified forms of LDL rather than on LDL itself because of the previous extensive literature showing that exposure to LDL does not result in significant cholesterol loading of macrophages, whereas acLDL does giving rise to the hypothesis that the major source of cholesterol loading in vivo is oxLDL [17,18]. The rationale to infer observations obtained using acLDL to oxidative modifications of LDL that occur in vivo was that both forms of the modified LDL are recognized and internalized by the same scavenger receptors [17]. However, a more detailed comparison of the actual impacts of acLDL and oxLDL on cellular cholesterol revealed that, at least in the endothelial cells, it is completely different: while exposure to the acLDL indeed loads endothelial cells with cholesterol, exposure to oxLDL does not but instead loads the cells with oxidized lipids, primarily oxysterols [19,20]. Oxysterols also incorporate into the plasma membrane but their effect on membrane structure is the opposite of that of cholesterol: while cholesterol increases lipid order of the membrane, oxysterols disrupt lipid order [21,22]. Recently, we showed that this is also true in macrophages, exposure of bone marrowderived macrophages to oxLDL resulted in loading the cells with 7ketocholesterol but not cholesterol [23]. Thus, we next determined if exposure to physiological levels of LDL may result in cholesterol loading of endothelial cells and found that this is indeed the case. Using mass spectrometry, we found that exposing human aortic endothelial cells to the LDL level observed in hypercholesterolemic patients (250 mg/dl) resulted in a significant increase in cholesterol/phospholipid ratio in the membrane, as compared to cells exposed to 50 mg/dl LDL, a level found in healthy individuals (~ 600 to ~ 750 pmol cholesterol/nmol phospholipid, respectively) [15]. This elevation of cholesterol was sufficient to result in a significant ordering of the membrane, as assessed by a Laurdan dye [15], sensitive to the water dipoles in the membrane [24,25]. Most recently, we found that exposure to increasing levels of LDL results in a gradual increase in endothelial free cholesterol with a slight but statistically significant increase in response to 150 mg/dl LDL and a relatively large twofold increase/ per mg protein, in response to 250 mg/dl LDL [16••]. It is noteworthy that exposing endothelial cells to MβCDcholesterol, high levels of LDL and to diet-induced hypercholesterolemia in vivo, all resulted in ~ twofold increase in cellular free cholesterol when normalized to protein, suggesting that this is the amount that cellular membranes can accommodate when exposed to hypercholesterolemic conditions.

Impact of Cholesterol Loading on Endothelial Function In Vitro
The next logical question is what is the impact of cholesterol loading on endothelial function? This question can be addressed in vitro by modulating cellular cholesterol level pharmacologically, particularly using MβCD, which provides a highly reproducible method to both deplete and enrich cells with cholesterol. However, depletion of cellular cholesterol, while definitely uncovering fundamental roles of cholesterol in cellular function, does not necessarily provide significant insights to the physiologically relevant conditions of cholesterol loading. Indeed, several examples were reported when cholesterol depletion had an effect on specific features/ functions, whereas cholesterol enrichment had no effect [26]. We focus here, therefore, on discussing endothelial dysfunction induced specifically by cholesterol enrichment.
An early work by Feron et al. [27] showed that exposing endothelial cells to serum obtained from hypercholesterolemic patients resulted in an increase in cellular abundance of a cholesterol binding protein, caveolin-1, a structural scaffolding protein of membrane invaginations called caveolae, known to be signaling hubs [28]. Caveolin-1 is also known to directly interact and regulate the function of multiple proteins, including negative regulation of endothelial nitric synthase, eNOS, an enzyme that produces NO [28]. Feron et al. also showed that an increase in caveolin-1 led to stabilization of caveolin-1-eNOS interaction and a decrease in eNOS function. However, even though caveolae constitute a membrane domain strongly enriched in cholesterol, it is not entirely clear whether an increase in the abundance of caveolin-1 was a result of an increase in membrane cholesterol. Our studies demonstrated a direct inhibitory effect of free cholesterol loading on endothelial inwardly rectifying K + channels (Kir2.1) [14,29], a flow-sensitive channel that has been proposed to be one of the putative endothelial flow sensors [30]. Furthermore, our extensive computational and structure-function studies revealed that cholesterol suppresses Kir channels via specific cholesterol-protein interactions [31,32] with the cholesterol molecules binding to multiple hydrophobic pockets of the channel transmembrane domains constituting non-annular cholesterol binding sites [33,34]. Notably cholesterolinduced suppression of Kir channels was shown to be independent of caveolin [35]. We further discovered that the mechanism by which cholesterol binding suppresses the activity of Kir2 channels is disrupting specific intramolecule residue-residue interaction that leads to the uncoupling of the channel subunits [36 •], which interferes with the channel gating [37,38]. In terms of the functional consequences of cholesterol-induced suppression of endothelial Kir channels, since functional expression of these channels is essential for the activation of a major flow-induced phosphorylation cascade of Akt1/ eNOS [39], their cholesterol suppression is expected to impair flow-induced production of NO. Additionally, Andrews et al. showed that cholesterol loading suppresses ATP-induced-induced capacitative Ca 2+ entry, indicating a decreased function of the STIM/ORAI complex that constitutes the capacitative Ca 2+ entry mechanism [40], which was accompanied with an inhibition of eNOS phosphorylation. Since capacitative Ca 2+ entry was shown earlier to contribute to agonist-and shear-stress activation of eNOS [41], the authors suggested that cholesterolinduced impairment of Ca 2+ entry might be responsible for the inhibition of eNOS. All these studies, however, focus on acute effects of free cholesterol loading on different endothelial proteins, and clearly complementary in vivo studies are needed to establish which of these mechanisms contribute to hypercholesterolemia-induced endothelial dysfunction.

Impact on Endothelial Function Following the Removal of Cholesterol Surplus from Hypercholesterolemic Animals
The beneficial effects of increased HDL and cholesterollowering therapies (e.g., statins) on endothelial function indicates that the removal of excess free cholesterol from endothelial membranes improves endothelial function in individuals with hypercholesterolemia [42,43]. Therefore, another approach to determine the role of excess cellular cholesterol on endothelial function is by experimentally removing the surplus of cholesterol from hypercholesterolemic animals in vivo and from tissue ex vivo. In this approach, the removal of excess cholesterol is predicted to restore the proper endothelial functions. For instance, Kaul et al. showed that in vivo infusions of a naturally occurring and antiatherosclerotic apolipoprotein variant established to have increased cholesterol efflux capacity reversed endothelial dysfunction in aortas of dyslipidemic apolipoprotein E deficient (Apoe −/− ) mice [44]. Apoe −/− mice receiving the apolipoprotein variant had significantly less aortic tissue cholesterol compared to control mice which corresponded to improved endothelial function. Importantly, these effects were independent of serum cholesterol which remained elevated in Apoe −/− mice receiving the apolipoprotein variant suggesting that the removal of tissue cholesterol specifically restores endothelial function [44]. However, these earlier studies did not mechanistically address how the removal of the cholesterol surplus from vascular tissue improved endothelial function nor was it determined if indirect systemic effects of the apolipoprotein afforded benefits to endothelial function in vivo. Therefore, we aimed to determine if the beneficial effect of the removal of a cholesterol surplus ex vivo in arteries from Apoe −/− mice was mediated by restoration of inwardly rectifying K + (Kir) channels. To achieve this goal, we exposed isolated mesenteric arteries to MβCD and performed pressure myography to assess endothelial function. As expected, arteries from Apoe −/− mice had blunted dilations to flow, a potent stimulus that induces NO via endothelial Kir channel activation [39, 45•]. In contrast, arteries from Apoe −/− mice exposed to MβCD prior to testing endothelial function exhibited comparable dilations to flow as that of arteries from WT mice. Indeed, Kir channel function was restored in this condition as Ba 2+ , an inhibitor of Kir channels, blunted the dilatory response to flow indicating that the removal of excess cholesterol from arteries of dyslipidemic mice restored endothelial function via recovery of Kir channel function. Furthermore, MβCD-induced recovery of the flow-induced dilation was abrogated in arteries of Apoe −/− mice crossed with Kir2.1-deficient mice, indicating that the recovery of 1 3 the dilations is Kir2.1 dependent. This finding was further supported by patch clamp electrophysiology experiments in freshly isolated endothelial cells from Apoe −/− mice where MβCD treatment resulted in a significant increase in Kir channel current [45•]. Taken together, these observations indicate that the removal of the cholesterol surplus in vivo or ex vivo has beneficial effects on endothelial function, likely through the restoration of Kir channel function upstream of NO production. However, the pan removal of excess cholesterol by promoting cholesterol efflux undoubtedly has multiple possible effects on endothelial function. To best address a specific contribution of Kir to cholesterol-induced endothelial dysfunction, we must specifically disrupt the ability of cholesterol to suppress Kir channels without reducing free cholesterol in the membrane.

Benefits to Endothelial Function by Rendering Proteins Insensitive to Cholesterol
The most direct approach in determining if cholesterol mediates endothelial dysfunction via direct effects on the function of a specific protein is to generate functional mutants that are insensitive to cholesterol-mediated suppression. In this approach, the cholesterol surplus accompanying dyslipidemia is maintained and only the role of the cholesterol-mediated suppression of the protein in inducing endothelial dysfunction is addressed. With regard to our findings detailing cholesterol-mediated suppression of endothelial Kir2.1 channels, our structure-function studies described above led to the identification of an array of mutations that (i) did not affect Kir channel function and (ii) rendered Kir channels insensitive to cholesterol-mediated suppression of channel function. We previously identified that the Kir2.1-L222I mutation matched these criteria [46]. Our next major goal was to determine if this cholesterol insensitive Kir2.1 mutant could restore endothelial function in a model of hypercholesterolemia. We generated Kir2.1-L222I transgenic mice using CRSPR-Cas9 gene editing and crossed them with Apoe −/− mice. We first tested Kir channel currents in freshly isolated endothelial cells to confirm that the Kir2.1-L222I channels had (i) larger currents than Apoe −/− controls containing WT Kir2.1 and (ii) restored flow-sensitivity. Indeed, endothelial cells from the Kir2.1-L222I Apoe −/− transgenic mice had larger Kir currents than the WT Kir2.1 Apoe −/− controls. Furthermore, in contrast to WT Kir2.1 channels in cells from Apoe −/− mice, the Kir2.1-L222I channels exhibited flowsensitivity indicating a complete restoration of function in the cholesterol-insensitive mutant channels [16••]. Most importantly, we next aimed to determine if rendering Kir channels insensitive to cholesterol prevented the dyslipidemia-induced endothelial dysfunction observed in WT Kir2.1 Apoe −/− controls. Arteries from the mice containing the Kir2.1-L222I mutation exhibited dilations to flow comparable to non-dyslipidemic, WT mice independent of the presence of dyslipidemia indicating that rendering By removing the surplus of cholesterol using methylβ-cyclodextrin (MβCD) or preventing cholesterol-mediated suppression of endothelial Kir channels (L222I mutation), we were able to restore endothelial function in a model of hypercholesterolemia. It is important to note that the L222I mutation does not disrupt the interaction between cholesterol and Kir2.1 but renders the channel insensitive to cholesterol-mediated suppression [46]. Figure created with BioRender.com Kir2.1 insensitive to cholesterol-mediated suppression was sufficient to restore endothelial function without removing the cholesterol surplus [16••]. Our findings, summarized in Fig. 1, support the targeting of cholesterol-induced suppression of proteins in restoring endothelial function in dyslipidemic conditions and promote the identification of similar mechanisms in distinct endothelial proteins.

Conclusion
The beneficial effects on endothelial function following the removal of the cholesterol surplus under hypercholesterolemic conditions are clear. However, we are just beginning to unveil the mechanisms related to specific cholesterol-protein interactions in mediating endothelial dysfunction. Our recent studies have detailed that the cholesterol-mediated suppression of Kir2.1 is a major and specific mechanism underlying hypercholesterolemiainduced endothelial dysfunction. Importantly, rendering this channel insensitive to cholesterol-mediated suppression of channel function restores endothelial function in the presence of elevated membrane cholesterol, thereby highlighting the potential benefits of targeting the effects of cholesterol on specific proteins. These findings may lead to an additional avenue in restoring endothelial function in dyslipidemic populations, perhaps in combination with lipid lowering therapies [47].
Funding Research reported in this publication was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under award number 2P20GM113125 to IF and by NIH R01 grants HL073965, HL141120, and HL083298 to IL.

Conflict of Interest
The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.